PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Coronary Artery Disease and Type 2 Diabetes Mellitus.

Abstract Type 2 diabetes mellitus (T2DM) is a major risk factor of coronary artery diseases (CAD). Clinical outcomes in CAD with T2DM are poor despite improvement in medications and intervention devices. Coronary artery bypass grafting (CABG) is superior to percutaneous coronary intervention (PCI) in treating diabetic patients with multivessel coronary artery diseases (MVD). However, selecting a revascularization strategy should depend not only on the lesion complexity but also on the patient's background and comorbidities. In addition, comprehensive risk management with medical and non-pharmacological therapies is important, as is confirmation of whether risk managements are appropriately achieved. Recently, novel anti-diabetic drugs have been demonstrated to have effectiveness in reducing cardiovascular events, which was independent of their glucose-lowering effect. Furthermore, non-pharmacological interventions using exercise and diet during the earlier stages of abnormal glucose metabolism might be beneficial in preventing the development or progression of T2DM and reducing the incidence of cardiovascular events.
PMID
Related Publications

Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review.

Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial.

Management of acute coronary syndromes in patients with diabetes: implications of the FREEDOM trial.

The Bypass Angioplasty Revascularization in Type 1 and Type 2 Diabetes Study: 5-year follow-up of revascularization with percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients with multivessel disease.

Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives.

Authors

Mayor MeshTerms
Keywords

Comprehensive risk management

GLP1 antagonist

Multivessel disease

Revascularization

SGLT2 inhibitor

Journal Title international heart journal
Publication Year Start




PMID- 28717115
OWN - NLM
STAT- Publisher
DA  - 20170718
LR  - 20170718
IS  - 1349-3299 (Electronic)
IS  - 1349-2365 (Linking)
DP  - 2017 Jul 14
TI  - Coronary Artery Disease and Type 2 Diabetes Mellitus.
LID - 10.1536/ihj.17-191 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a major risk factor of coronary artery
      diseases (CAD). Clinical outcomes in CAD with T2DM are poor despite improvement
      in medications and intervention devices. Coronary artery bypass grafting (CABG)
      is superior to percutaneous coronary intervention (PCI) in treating diabetic
      patients with multivessel coronary artery diseases (MVD). However, selecting a
      revascularization strategy should depend not only on the lesion complexity but
      also on the patient's background and comorbidities. In addition, comprehensive
      risk management with medical and non-pharmacological therapies is important, as
      is confirmation of whether risk managements are appropriately achieved. Recently,
      novel anti-diabetic drugs have been demonstrated to have effectiveness in
      reducing cardiovascular events, which was independent of their glucose-lowering
      effect. Furthermore, non-pharmacological interventions using exercise and diet
      during the earlier stages of abnormal glucose metabolism might be beneficial in
      preventing the development or progression of T2DM and reducing the incidence of
      cardiovascular events.
FAU - Naito, Ryo
AU  - Naito R
AD  - Heart Center, Juntendo University Urayasu Hospital.
FAU - Miyauchi, Katsumi
AU  - Miyauchi K
AD  - Department of Cardiovascular Medicine, Juntendo University Graduate School of
      Medicine.
LA  - eng
PT  - Journal Article
DEP - 20170714
PL  - Japan
TA  - Int Heart J
JT  - International heart journal
JID - 101244240
OTO - NOTNLM
OT  - Comprehensive risk management
OT  - GLP1 antagonist
OT  - Multivessel disease
OT  - Revascularization
OT  - SGLT2 inhibitor
EDAT- 2017/07/19 06:00
MHDA- 2017/07/19 06:00
CRDT- 2017/07/19 06:00
AID - 10.1536/ihj.17-191 [doi]
PST - aheadofprint
SO  - Int Heart J. 2017 Jul 14. doi: 10.1536/ihj.17-191.